Ligand Pharma (Nasdaq: LGND) announced that data from a Phase 1 study of the selective estrogen receptor modulator (SERM) lasofoxifene ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE